Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00066404 · ClinicalTrials.gov registry record · Phase 1
Intrapleural BG00001 in Treating Patients With Malignant Pleural Mesothelioma or Malignant Pleural Effusions
A Phase 1 study, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00066404: Completed Phase 1 study, sponsored by Abramson Cancer Center at Penn Medicine.
NCT00066404 is a Phase 1 study that has completed, run by Abramson Cancer Center at Penn Medicine. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00066404, a Phase 1 study, has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Using BG00001 to insert the gene for interferon-beta into a person's pleural cavity may improve the body's ability to fight cancer. PURPOSE: Phase I trial to study the effectiveness of intrapleural BG00001 in treating patients who have malignant pleural mesothelioma or malignant pleural effusions.
Interventions
- BIOLOGICAL recombinant adenovirus-hIFN-beta
Trial Details
| Field | Value |
|---|---|
| Start Date | 2003-04 |
| Est. Completion | 2006-01 |
| Phase | Phase 1 |
What the finished NCT00066404 record still lists
NCT00066404 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which recombinant adenovirus-hIFN-beta is the first listed.
NCT00066404 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00066404 about?
NCT00066404 is a clinical study titled "Intrapleural BG00001 in Treating Patients With Malignant Pleural Mesothelioma or Malignant Pleural Effusions". RATIONALE: Using BG00001 to insert the gene for interferon-beta into a person's pleural cavity may improve the body's ability to fight cancer. PURPOSE: Phase I trial to study the effectiveness of intrapleural BG00001 in treating patients who have malignant pleural mesothelioma or malignant pleural ...
What is the current status of trial NCT00066404?
This trial is currently completed. It is a Phase 1 study. The study started on 2003-04. Estimated completion is 2006-01.
What interventions are being tested in trial NCT00066404?
The interventions under investigation include: recombinant adenovirus-hIFN-beta (BIOLOGICAL).
Who is sponsoring clinical trial NCT00066404?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia